GlassScriptPhysician profile
Jamie M Boyce
NPI 1508078924
$2,048.27
in general payments reported to CMS, 2019-2025
32 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $84.04 · 2021: $591 · 2022: $396 · 2023: $185 · 2024: $130 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.78 | 2019-2022 | |
| Hologic Sales and Service, LLC | $326.44 | 2019-2024 | Aptima |
| Mayne Pharma Commercial LLC | $217.00 | 2021-2025 | |
| Aspira Women'S Health INC | $143.16 | 2022 | |
| Therapeuticsmd, INC. | $129.69 | 2021-2022 | |
| Coopersurgical, INC. | $103.22 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $89.33 | 2021-2024 | |
| Alydia Health | $70.56 | 2021 | |
| Millicent US INC | $60.51 | 2025 | Femlyv, Intrarosa |
| Exeltis, USA INC. | $59.13 | 2020-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $56.55 | 2019-2023 | |
| Myovant Sciences INC. | $55.06 | 2021-2022 | |
| Davol INC. | $47.30 | 2022-2023 | Arista Ah Flexitip |
| Minerva Surgical, INC | $26.68 | 2019 | |
| Agile Therapeutics, INC. | $24.01 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $22.58 | 2021 | |
| Channel Medsystems, INC. | $22.00 | 2022 | |
| Medicem INC. | $19.81 | 2021 | |
| Astellas Pharma US INC | $19.79 | 2024 | Veozah |
| Amag Pharmaceuticals, INC. | $19.11 | 2019 | |
| Sumitomo Pharma America, INC. | $18.26 | 2024 | Myfembree |
| Merck Sharp & Dohme LLC | $18.04 | 2021 | |
| Abbott Laboratories | $18.03 | 2024 | Proclaim |
| Axsome Therapeutics, INC. | $17.26 | 2025 | Auvelity |
| Boston Scientific Corporation | $15.68 | 2019 | |
| Shield Therapeutics INC | $15.52 | 2023 | Accrufer |
| Sage Therapeutics, LLC | $14.32 | 2021 | |
| Lupin INC. | $14.30 | 2019 | |
| Novo Nordisk INC | $13.72 | 2023 | Saxenda, Wegovy |
| Avion Pharmaceuticals | $12.66 | 2021 | |
| Organon LLC | $10.34 | 2021 | |
| Meditrina | $9.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Boyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.